TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01727843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: drug and placebo applied topically at end of surgery at hip site.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: applied topically to surgical site in OR.
Study: NCT01404975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB)
Description: We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block (PVB)
Description: We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines.
Study: NCT01251744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood sample
Description: Cord blood sample taken at the time of delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood sample
Description: Cord blood sample taken at the time of delivery.
Study: NCT02578641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous EBV specific Cytotoxic T cells
Description: The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination IV gemcitabine and IV carboplatin (AUC2)
Description: 4 cycles for Arm A and 6 cycles for Arm B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination IV gemcitabine and IV carboplatin (AUC2)
Description: 4 cycles for Arm A and 6 cycles for Arm B
Study: NCT03428945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine for oral administration, dosed by weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to active drug
Study: NCT02463630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Approach Compression Distraction Reduction
Description: Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
Study: NCT02870439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawn

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawn
Study: NCT02745860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (adult formulation)
Description: One selexipag film-coated tablet of 200 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (adult formulation)
Description: One selexipag film-coated tablet of 200 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (pediatric formulation)
Description: Four selexipag film-coated tablets of 50 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (pediatric formulation)
Description: Four selexipag film-coated tablets of 50 µg
Study: NCT00779441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg tablets
Study: NCT04325607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of HS followed by NPWTi
Description: The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
Study: NCT02005562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-2R
Description: Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-IL-2R
Description: Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: 100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: 100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
Study: NCT02910596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bethanechol chloride
Description: bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early bladder training
Description: early bladder training start on 3rd - 5thpostoperative day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early bladder training and bethanechol chloride
Description: bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day

Intervention type: OTHER
Group type: OTHER
Intervention: no early bladder training and no bethanechol chloride
Description: no bethanechol chloride and no early bladder training
Study: NCT04325607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of HS followed by NPWT
Description: The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
Study: NCT02058160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide (HOE901/AVE0010)
Description: Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Background Drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (Background Drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration
Study: NCT02480608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study: NCT02571309

Intervention type: DEVICE
Group type: OTHER
Intervention: Asthmatuner
Description: Asthmatuner is an app for self-management of asthma.

Intervention type: DEVICE
Group type: OTHER
Intervention: Asthmatuner
Description: Asthmatuner is an app for self-management of asthma.
Study: NCT01138345

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood samples will be analyzed for the expression of the p16 gene.

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood samples will be analyzed for the expression of the p16 gene.

Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood samples will be analyzed for the expression of the p16 gene.

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: perform reverse transcriptase-polymerase chain reaction on all blood samples.

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: perform reverse transcriptase-polymerase chain reaction on all blood samples.

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: perform reverse transcriptase-polymerase chain reaction on all blood samples.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: perform laboratory biomarker analysis on all blood samples

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: perform laboratory biomarker analysis on all blood samples

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: perform laboratory biomarker analysis on all blood samples

Intervention type: OTHER
Intervention: medical chart review
Description: perform medical chart review for all subjects

Intervention type: OTHER
Intervention: medical chart review
Description: perform medical chart review for all subjects

Intervention type: OTHER
Intervention: medical chart review
Description: perform medical chart review for all subjects

Intervention type: OTHER
Intervention: questionnaire administration
Description: each cohort will be given the same questionnaire

Intervention type: OTHER
Intervention: questionnaire administration
Description: each cohort will be given the same questionnaire

Intervention type: OTHER
Intervention: questionnaire administration
Description: each cohort will be given the same questionnaire
Study: NCT03976934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: administration of tamsulosin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: sugar pills
Study: NCT02319057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741
Study: NCT01690325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study: NCT01251744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
Study: NCT01690325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Study: NCT04206943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Car-T Cell Therapy
Description: Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Car-T Cell Therapy
Description: Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements.
Study: NCT03652428

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: see arm description

Intervention type: RADIATION
Group type: OTHER
Intervention: Hypofractionated Ablative Proton Therapy
Description: see arm description
Study: NCT01740518

Intervention type: DRUG
Intervention: polyethylene glycol, ascorbic acid
Description: comparison of different solutions for bowel preparation
Study: NCT01251744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
Study: NCT01670604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetraspan, B. Braun, Melsungen, Germany
Study: NCT01264016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Study: NCT03376906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIE 1
Description: In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIE 3
Description: In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
Study: NCT00121264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT03433274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip System
Description: Percutaneous mitral valve repair using the MitraClip system.
Study: NCT02913196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Dose: 5 mg BID
Study: NCT01085617

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: palifermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palifermin
Study: NCT00121264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01085617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study: NCT00121264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies